Literature DB >> 17934381

Quetiapine for mania due to traumatic brain injury.

Timothy J Oster1, C Alan Anderson, Christopher M Filley, Hal S Wortzel, David B Arciniegas.   

Abstract

Secondary mania develops in as many as 9% of persons with traumatic brain injuries. The treatment of posttraumatic mania is not well defined, and agents traditionally used for the treatment of idiopathic manic episodes may not be well suited for use among individuals with traumatic brain injuries. Atypical antipsychotics are indicated for the treatment of idiopathic bipolar disorder, and have been used for other purposes among individuals with posttraumatic neuropsychiatric disturbances. This article offers the first description of the treatment of posttraumatic mania using the atypical antipsychotic quetiapine. Beneficial effects of this agent on posttraumatic mania, cognitive impairments, and functional disability in the subacute post-injury period are described. Possible mechanisms of action are discussed and the need for additional investigation of quetiapine for posttraumatic mania is highlighted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934381     DOI: 10.1017/s1092852900015455

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  3 in total

Review 1.  Mood disorders after TBI.

Authors:  Ricardo E Jorge; David B Arciniegas
Journal:  Psychiatr Clin North Am       Date:  2014-01-14

2.  Psychiatric disorders and traumatic brain injury.

Authors:  Marcelo Schwarzbold; Alexandre Diaz; Evandro Tostes Martins; Armanda Rufino; Lúcia Nazareth Amante; Maria Emília Thais; João Quevedo; Alexandre Hohl; Marcelo Neves Linhares; Roger Walz
Journal:  Neuropsychiatr Dis Treat       Date:  2008-08       Impact factor: 2.570

3.  A Case Report of Mania and Psychosis Five Months after Traumatic Brain Injury Successfully Treated Using Olanzapine.

Authors:  Giordano F Cittolin-Santos; Jesse C Fredeen; Robert O Cotes
Journal:  Case Rep Psychiatry       Date:  2017-06-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.